Nettet14. mar. 2024 · Intellia Therapeutics GAAP EPS of -$1.40 misses by $0.04, revenue of $13.6M beats by $2.89M. Seeking Alpha 27d. Nettet13. apr. 2024 · 1. Intellia Therapeutics Gene-editing specialist Intellia Therapeutics has admittedly been a stress-inducing investment over the past year as its share price is down about 45%. The company generated $52 million in revenue last year but it incurred a net loss of $474 million.

Intellia: Slim Hopes Of Near-Term Commercial Revenue, Bearish

Nettet10. jul. 2024 · Healthcare is undergoing a genomics revolution, and Intellia Therapeutics (NASDAQ: NTLA) is leading the way. Founded by Jennifer Doudna, who won the 2024 Nobel Prize in Chemistry for her... Nettet30. mar. 2024 · On paper, it’s a win-win scenario for patients and investors. Still, this segment can be incredibly volatile. But if you can handle the heat, these biotech stocks to buy may offer a breakthrough ... chanatip arm amnuay

Intellia Stock

Nettet13. apr. 2024 · Intellia Therapeutics Inc. (NASDAQ:NTLA) shares, rose in value on Thursday, April 13, with the stock price up by 10.82% to the previous day’s close as strong demand from buyers drove the stock to $38.32. Actively observing the price movement in the recent trading, the stock is buoying the session NettetIn November 2014, Intellia Therapeutics raised $15 million in Series A round. [27] In September 2015, a Series B round secured $70 million. [28] In May 2016, Intellia announced the closing of its initial public offering which … Nettet2. jul. 2024 · Intellia Therapeutics is developing a drug for a rare and fatal disease known as transthyretin amyloidosis in collaboration with Regeneron. The drug is in phase 1 trials currently. The company... chanathorn supplys center co. ltd